Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹15,469.1 Cr
verified against source
Revenue YoY
15.1%
reported change
EBITDA
₹4,948.5 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sun Pharma delivered a strong Q3 FY26 with consolidated revenue of INR 15,469 crore (+15.1% YoY) and EBITDA of INR 4,949 crore (+23.4% YoY), driven by broad-based growth in India (+16.2%) and emerging markets (+21.6%), partially offset by flat US sales. EBITDA margin expanded to 31.9% on better product mix, while PAT grew 16% to INR 3,369 crore despite a higher tax rate. Management highlighted the upcoming launch of generic semaglutide in India as a key growth catalyst, with approvals received for both diabetes and weight management. However, US generic sales remain under pressure from competition and manufacturing compliance issues, and the company faces uncertainty from proposed US pricing reforms. The strong balance sheet (net cash $3.2B) provides M&A flexibility, though management remains disciplined.
Colored figures show movement against the previous available record.
Guidance to track
- Sun Pharma plans to launch generic semaglutide in India on day one of patent expiry for both chronic weight management and type 2 diabetes, under brands NovelTreat and SemaTrinity.
- Management indicated they will provide R&D spend guidance for the next fiscal year in the next quarter's call.
- The phase 2b study for GL0034 in type 2 diabetes has started and is expected to complete within 12-18 months.
Risks flagged
- US generic sales declined due to additional competition on certain products, and recovery depends on resolving manufacturing compliance issues at several sites.
- CMS proposed pricing models could impact US revenues; management declined to share mitigation strategies, citing commercial sensitivity.
- Effective tax rate rose to ~25% from ~15% last year, dampening PAT growth relative to EBITDA growth; expected to remain in that range.
- Management noted that milestone income of $55 million in Q3 may not recur in future quarters, potentially impacting revenue comparability.
Key quotes
- Our focus is on finding a way to grow our business organically at a rate, so that we continue to be an attractive investment opportunity for shareholders. We would look at an acquisition only if we think that it can help us in terms of strengthening our long-term strategic capability.
- What it really offers is balance between efficacy and tolerability. So Enloxit works three ways: It restores adaptive immunity, which is by binding to the PD-L1. It engages the innate immune system based on its active Fc domain that activates natural killer cells, and unlike the existing products, it preserves PD-L2 signaling.
- We are very excited to launch the product on the patent expiry. When the generic product for Sema is launched, it will also improve the access, and the market will expand.
Research modules